Intellia Therapeutics, Inc.
- Last sale
- Nov 12, 2026 · -7.54%
- Market cap
- $1.48B
- 140.36M shares
- Filings
- 726
Q3 2026+16.9% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026−17.8% FY25 yoy
- $1.48B
- —
- 28.0×
- 2.4×
- -24.18%
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $67,671,000 | reported | |
| FY 2024 | 2024-12-31 | $57,877,000 | reported | |
| FY 2023 | 2023-12-31 | $36,275,000 | reported | |
| FY 2022 | 2022-12-31 | $52,121,000 | reported | |
| FY 2021 | 2021-12-31 | $33,053,000 | reported | |
| FY 2020 | 2020-12-31 | $57,994,000 | reported | |
| FY 2019 | 2019-12-31 | $43,103,000 | reported | |
| FY 2018 | 2018-12-31 | $30,434,000 | reported | |
| FY 2017 | 2017-12-31 | $26,117,000 | reported | |
| FY 2016 | 2016-12-31 | $16,479,000 | reported |
In vitro & in vivo diagnostic substances
Intellia Therapeutics, Inc. is the 6th largest of the 20 covered companies the SEC files under this code, by revenue. SIC 2835
CompanyRevenueGrowthNet marginMarket cap
NEOGNeogen Corp$870.4M2.7%0.9%$2.4BMYGNMyriad Genetics Inc$824.5M1.6%44.4%$544.8M
NTLAIntellia Therapeutics, Inc. (this company)$67.7M16.9%609.9%$1.5B
TKNOAlpha Teknova, Inc.$40.5M7.4%42.6%$521.8MICCCImmucell Corp$27.6M4.3%3.8%$89.6MAWHLAspira Women's Health Inc.$9.2M0.4%138.7%$16.3MNNNNAnbio Biotechnology$8.6M5.6%74.1%$554.7MBMRABiomerica Inc$4.5M16.2%84.8%$5.9MIMDXInsight Molecular Diagnostics Inc.$4.1M115.6%1,238.5%$75.3MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Intellia Therapeutics, Inc. · CIK 1652130 · Engraved from SEC EDGAR